From class waivers to precision medicine in paediatric oncology
- 1 July 2017
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 18 (7), e394-e404
- https://doi.org/10.1016/s1470-2045(17)30442-4
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Implementation of mechanism of action biology-driven early drug development for children with cancerEuropean Journal of Cancer, 2016
- Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancerEuropean Journal of Cancer, 2014
- Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?Clinical Cancer Research, 2013
- Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countriesThe Lancet Oncology, 2013
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Long-term Cause-Specific Mortality Among Survivors of Childhood CancerJAMA, 2010
- The role of the ‘innovative therapies for children with cancer’ (ITCC) European consortiumCancer Treatment Reviews, 2010
- Survival of European children and young adults with cancer diagnosed 1995–2002European Journal of Cancer, 2009
- Long-term follow-up of people who have survived cancer during childhoodThe Lancet Oncology, 2006